St Jude on track for 2012 EU launch of Portico transcatheter heart valve
This article was originally published in Clinica
St Jude Medical has implanted the first patient with its Portico transcatheter aortic heart valve in a European study designed to support CE mark approval. It means the company is on track to launch the valve in Europe by the end of 2012 on a limited basis; however, rival Edwards Lifesciences is likely to remain the leader in the transcatheter aortic valve implantation (TAVI) over the long term, according to Morgan Stanley analyst David Lewis.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.